Global Thrombocytopenia TreatmentMarket Dynamics
The ThrombocytopeniaTreatment Market is driven by increasing prevalence of thrombocytopenia globally.The risk of developing thrombocytopenia is much higher for chronic Hepatitis Ccases. In 2014, according to World Health Organization (WHO), the prevalence ofHepatitis C was lower in Americas and Europe as compared to Africa andPakistan, where the prevalence of chronic liver disorder was 4-6 % higher thanthat in Americas and Europe. Liver disease has become a socio economic andglobal health problem, as 60-80% of the population develops the disease.Furthermore, increasing government support for fast-track approval to discovernewer treatments for this disorder and increasing investment in the developmentof new drugs by biotechnology and pharmaceutical companies are expected topropel growth of the thrombocytopenia treatment market during the forecastperiod. However, from 2023, thrombocytopenia treatment market is projected towitness a slowdown in growth due to patent expiration and increasingavailability of generics of Promacta and MabThera.
Thrombocytopenia is a disorder inwhich a patient has low level of platelets in the blood. The major causes ofthrombocytopenia are inefficient production of platelets, platelet splenicsequestration, and accelerative destruction of platelets. The most commonineffective production of thrombocytes are due bone marrow failure syndromesuch as myelodysplastic syndrome and aplastic anemia. Thrombocytopenia can beinherited or acquired. In 2014, According to a research article published inProfessional Med J, 2014, entitled Frequency of Thrombocytopenia, the frequencyof thrombocytopenia is higher for people aged 60 years and above, sufferingfrom non-cirrhotic liver disease. However, rampant discovery coupled with theability to clone thrombopoietin has resulted in new treatment opportunities forclinical manifestation.
* The sample copy includes: Report Summary, Table of Contents,Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1484
More specific treatment plansusually depend on the underlying etiology of thrombocytopenia. In most casesthe underlying cause of thrombocytopenia is not known, especially in the caseof severe bleeding. In September 2015, Lusutrombopag, an orally bioavailable,small molecule thrombopoietin (TPO) receptor agonist developed by ShionogiInc., received approval by Pharmaceuticals and Medical Devices Agency of Japan.Lusutrombopag helped enhance chronic liver disease (CLD) associated withthrombocytopenia for patients scheduled to undergo invasive procedures.Lusustrombopag acts specifically on human thrombopoietin (TPO) receptors andstimulates signaling pathways that trigger the proliferation anddifferentiation of bone marrow cells into megakaryocytes. Thus, increasing theblood platelet count. However, patients treated with Lusustrombopag furthershowed higher counts of blood leukocytes and erythrocyte. Furthermore, in June2017, FDA accepted application for new oral investigational drug, Tavalisse(fostamatinib disodium), by Rigel Pharmaceuticals, Inc. This drug is designedto inhibit the spleen tyrosine kinase and treat patients suffering from chronicor persistent immune thrombocytopenia.
Another drug Eltrombopag byNovartis, an oral, non-peptide thrombopoietin receptor agonist has shownefficacy and safety for patients suffering from chronic immune thrombocytopenia(CIT). The use of this drug is approved in the U.S and registered in Europe.The low dose of Eltrombopag is effective and safe for the prevention of CIT.Case Reports Hematology, 2017, reports that long-term usage of thrombopoetin(TPO) receptor agonists is safe for patients suffering from chronic lymphocyticleukemia associated with Immune thrombocytopenia, as they are anon-immunosuppressive drugs.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/thrombocytopenia-treatment-market-1484
Global Thrombocytopenia TreatmentMarket – Competitors
Major players in thrombocytopeniatreatment market include 3SBio Inc., Amarillo Biosciences, Inc., Amgen Inc.,Baxalta Incorporated, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers SquibbCompany, Cellerant Therapeutics, Inc., Eisai Co., Ltd., Hansa Medical AB, IntasPharmaceuticals Ltd., Merck & Co., Inc., Momenta Pharmaceuticals, Inc.,Myelo Therapeutics GmbH, Neumedicines Inc., Novartis AG, Pfizer Inc., ProphylixPharma AS, Rigel Pharmaceuticals, Inc., Shionogi & Co., Ltd., STATegics,Inc., and ViroMed Co., Ltd.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1484
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
